Reviewing RECIST in the Era of Prolonged and Targeted Therapy.
暂无分享,去创建一个
[1] R. Doebele,et al. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[3] A. Shaw,et al. Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study. , 2017 .
[4] Erich P Huang,et al. Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database. , 2017 .
[5] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[6] Robert Ford,et al. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. , 2016, European journal of cancer.
[7] Erich P Huang,et al. RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.
[8] R. Doebele,et al. Exploratory responder analyses of greatest depth of response (DepOR) and survival in patients with metastatic non-small cell lung cancer (mNSCLC) treated with a targeted therapy or immunotherapy. , 2016 .
[9] D. Ettinger,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] R. Camidge,et al. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] M. Socinski,et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. , 2016, The Lancet. Oncology.
[12] U. Mansmann,et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). , 2015, European journal of cancer.
[13] H. Goldschmidt,et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma , 2015, Haematologica.
[14] Lucio Crinò,et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Martin Bendszus,et al. Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.
[16] Sean Khozin,et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Cho,et al. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis , 2015, Journal of Cancer.
[18] W. Pao,et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.
[19] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[20] R. Doebele,et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. , 2014, International journal of radiation oncology, biology, physics.
[21] D. Sargent,et al. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Susan M. Chang,et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. , 2013, The Lancet. Oncology.
[23] D. Camidge. Taking aim at ALK across the blood-brain barrier. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] C. Sima,et al. Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] P. Bunn,et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] C. Sima,et al. Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker , 2012, Clinical Cancer Research.
[27] A. Stoffel,et al. Targeted Therapies for Solid Tumors , 2010, BioDrugs.
[28] D. Dingli,et al. Relationship between depth of response and outcome in multiple myeloma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[30] Eudocia Q Lee,et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. , 2018, The Lancet. Oncology.
[31] Edward S. Kim,et al. P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical , 2017 .
[32] D. Sargent,et al. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. , 2014, European journal of cancer.
[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.